**Table S1:** GI cancers therapies using medication

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer type** | **Chemotherapy** | **Targeted therapy** | **Immunotherapy** | **Combined therapy** |
| **Pancreatic Cancer** | * Capecitabine * Fluorouracil * Gemcitabine * Irinotecan * Leucovorin * Nab-paclitaxel * Nanoliposomal irinotecan * Oxaliplatin | Cancer with an NTRK fusion:   * Larotrectinib * Entrectinib   BRCA1 or BRCA2 mutation:   * Olaparib   Anti-EGFR:   * Erlotinib | Anti-PD-1 antibodies for treating (MSI-H) or (dMMR) PC:   * Pembrolizumab * Dostarlimab | Metastatic PC:   * Combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin, called FOLFIRINOX * Gemcitabine plus nab-paclitaxel * gemcitabine plus cisplatin, gemcitabine plus capecitabine, or FOLFOX. * Fluorouracil, nanoliposomal irinotecan, irinotecan * Gemcitabine, nab-paclitaxel |
| **Colorectal Cancer** | * Capecitabine * Fluorouracil * Irinotecan * Oxaliplatin * Trifluridine/tipiracil | Anti-angiogenesis therapy:   * Bevacizumab * Regorafenib * Ziv-aflibercept * Ramucirumab   Anti-EGFR:   * Cetuximab * Panitumumab   BRAF inhibitor:   * Encorafenib   Cancer with an NTRK fusion:   * Larotrectinib * Entrectinib | Anti-PD-1 antibodies:   * Dostarlimab (Recurrent or metastatic colorectal cancers that have dMMR) * Pembrolizumab (fro (MSI-H) or (dMMR) CRC) * Nivolumab (Metastatic (MSI-H) or (dMMR) CRC)   Combination of immune checkpoint inhibitors:   * Nivolumab and ipilimumab (Metastatic (MSI-H) or (dMMR) CRC) | Combined targeted therapy for BRAF V600E:   * Encorafenib and Cetuximab   Common combined therapies:   * 5-FU with leucovorin * FOLFOX: 5-FU with leucovorin and oxaliplatin * 5-FU with leucovorin and irinotecan * Capecitabine with irinotecan   Capecitabine with oxaliplatin |
| **Liver Cancer** |  | Anti-angiogenesis therapy:   * Regorafenib * Ramucirumab * Bevacizumab * Ramucirumab   Tyrosine kinase inhibitors   * Lenvatinib * Sorafenib * Cabozantinib | Immune checkpoint inhibitors:   * Pembrolizumab * Nivolumab * Ipilimumab | First-line treatment:   * Bevacizumab with atezolizumab (advanced HCC) * Sorafenib or lenvatinib with bevacizumab   Second-line treatment for advanced HCC):   * Atezolizumab and bevacizumab |
| **Esophageal Cancer** | * Paclitaxel | HER2-targeted therapy:   * Trastuzumab * Trastuzumab deruxtecan   Anti-angiogenesis therapy:   * Ramucirumab | Anti-PD-1 antibodies:   * Pembrolizumab * Nivolumab |  |
| **Gastric cancer**  **Gastric cancer** | Cisplatin (available as a generic drug)  Oxaliplatin  Fluorouracil  Capecitabine  Docetaxel  Epirubicin  Irinotecan  Paclitaxel | HER2-targeted therapy:   * Trastuzumab   Anti-angiogenesis therapy:   * Ramucirumab | Anti-PD-1 antibodies:   * Pembrolizumab |  |